New drug tested for Tough-to-Treat blood cancers
NCT ID NCT06018506
Summary
This early-stage study tested a new drug called BR108 injection in adults with advanced blood cancers that had returned or stopped responding to other treatments. The main goal was to check the safety, side effects, and how the body processes the drug. The study was terminated after enrolling 8 participants.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEMATOLOGIC MALIGNANCY are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Tianjin Medical University Cancer Institute and Hospital
Tianjin, Tianjin Municipality, 300060, China
Conditions
Explore the condition pages connected to this study.